B-cell depletion in Wegener's granulomatosis

Clinical Reviews in Allergy and Immunology

Volumn 34, Issue 3, 2008, Pages 372-379

  Hinze, Claas H ^a   Colbert, Robert A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Anti neutrophil cytoplasmic antibodies (ANCA); B cell activating factor of the tumor necrosis factor (TNF) family (BAFF); B cell depletion; Rituximab; Small vessel vasculitis; Wegener's granulomatosis (WG)

Indexed keywords

ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; B CELL ACTIVATING FACTOR RECEPTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; MERCAPTOPURINE; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB; THYMOCYTE ANTIBODY;

ARTICLE; B CELL DEPLETION THERAPY; B LYMPHOCYTE; CELL THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LYMPHOCYTE DEPLETION; PATHOGENESIS; PATIENT SAFETY; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CHRONIC DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; WEGENER GRANULOMATOSIS;

EID: 49349101326     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-007-8057-7     Document Type: Article

References (58)

1. H Klinger 1931 Grenzformen der Periarteritis nodosa Frankf Z Pathol 42 455 480
2. F Wegener 1939 Über eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren Beitr Pathol Anat 109 36 68
3. AJ Mohammad LT Jacobsson AD Mahr G Sturfelt M Segelmark 2007 Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden Rheumatology (Oxford) 46 8 1329 1337
4. D Hollander RT Manning 1967 The use of alkylating agents in the treatment of Wegener's granulomatosis Ann Intern Med 67 2 393 398
5. GS Hoffman GS Kerr RY Leavitt 1992 Wegener granulomatosis: an analysis of 158 patients Ann Intern Med 116 6 488 498
6. FJ van der Woude N Rasmussen S Lobatto 1985 Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis Lancet 1 8426 425 429
7. X Bosch A Guilabert J Font 2006 Antineutrophil cytoplasmic antibodies Lancet 368 9533 404 418
8. GS Hoffman U Specks 1998 Antineutrophil cytoplasmic antibodies Arthritis Rheum 41 9 1521 1537
9. H Locht T Skogh A Wiik 2000 Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis Ann Rheum Dis 59 11 898 903
10. JD Finkielman AS Lee AM Hummel 2007 ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis Am J Med 120 7 643
11. MM Boomsma CA Stegeman MJ van der Leij 2000 Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study Arthritis Rheum 43 9 2025 2033
12. DJ Schlieben SM Korbet RE Kimura 2005 Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs Am J Kidney Dis 45 4 758 761
13. H Xiao P Heeringa P Hu 2002 Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice J Clin Invest 110 7 955 963
14. E Csernok 2003 Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides Autoimmun Rev 2 3 158 164
15. AA Rarok PC Limburg CG Kallenberg 2003 Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies J Leukoc Biol 74 1 3 15
16. D Albert C Clarkin J Komoroski 2004 Wegener's granulomatosis: possible role of environmental agents in its pathogenesis Arthritis Rheum 51 4 656 664
17. CA Stegeman JW Tervaert WJ Manson WL de Jong PE Sluiter 1994 Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis Ann Intern Med 120 1 12 17
18. CA Stegeman JW Tervaert PE de Jong 1996 Trimethoprim-sulfamethoxazole (cotrimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group N Engl J Med 335 1 16 20
19. E Csernok A Trabandt A Muller 1999 Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation Arthritis Rheum 42 4 742 750
20. DK Heffner 2002 Wegener's granulomatosis is not a granulomatous disease Ann Diagn Pathol 6 5 329 333
21. J Voswinkel A Mueller JA Kraemer 2006 B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions Ann Rheum Dis 65 7 859 864
22. P Youinou 2007 B cell conducts the lymphocyte orchestra J Autoimmun 28 2-3 143 151
23. M Krumbholz U Specks M Wick 2005 BAFF is elevated in serum of patients with Wegener's granulomatosis J Autoimmun 25 4 298 302
24. KP Baker 2004 BLyS - an essential survival factor for B cells: basic biology, links to pathology and therapeutic target Autoimmun Rev 3 5 368 375
25. F Atzeni A Doria T Maurizio 2007 What is the role of rituximab in the treatment of rheumatoid arthritis? Autoimmun Rev 6 8 553 558
26. A Thatayatikom AJ White 2006 Rituximab: a promising therapy in systemic lupus erythematosus Autoimmun Rev 5 1 18 24
27. GS Cheema V Roschke DM Hilbert 2001 Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases Arthritis Rheum 44 6 1313 1319
28. P Scapini A Carletto B Nardelli 2005 Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases Blood 105 2 830 837
29. JP Lynch 3rd E White H Tazelaar 2004 Wegener's granulomatosis: evolving concepts in treatment Semin Respir Crit Care Med 25 5 491 521
30. CA Langford C Talar-Williams KS Barron 1999 A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance Arthritis Rheum 42 12 2666 2673
31. U Specks 2005 Methotrexate for Wegener's granulomatosis: what is the evidence? Arthritis Rheum 52 8 2237 2242
32. D Jayne N Rasmussen K Andrassy 2003 A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies N Engl J Med 349 1 36 44
33. JH Stone ML Uhlfelder DB Hellmann 2001 Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety Arthritis Rheum 44 5 1149 1154
34. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352(4):351-361
35. CM Lockwood S Thiru S Stewart 1996 Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies QJM 89 12 903 912
36. WH Schmitt EC Hagen I Neumann 2004 Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients Kidney Int 65 4 1440 1448
37. PJ Klemmer W Chalermskulrat MS Reif 2003 Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis Am J Kidney Dis 42 6 1149 1153
38. MC Sneller 2005 Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum 52 1 1 5
39. GC Tsokos 2004 B cells, be gone - B-cell depletion in the treatment of rheumatoid arthritis N Engl J Med 350 25 2546 2548
40. M Pitashny Y Shoenfeld 2005 B cell depletion in autoimmune rheumatic diseases Autoimmun Rev 4 7 436 441
41. F Perosa E Favoino MA Caragnano 2005 CD20: a target antigen for immunotherapy of autoimmune diseases Autoimmun Rev 4 8 526 531
42. ME Reff K Carner KS Chambers 1994 Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 2 435 445
43. CH Hinze AA Grom 2007 B cell depletion: on the rise J Pediatr 150 4 335 337
44. MJ Leandro G Cambridge MR Ehrenstein 2006 Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis Arthritis Rheum 54 2 613 620
45. C Popa MJ Leandro G Cambridge 2007 Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs Rheumatology (Oxford) 46 4 626 630
46. KA Keogh ME Wylam JH Stone 2005 Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum 52 1 262 268
47. R Omdal K Wildhagen T Hansen 2005 Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response Scand J Rheumatol 34 3 229 232
48. AJ Ferraro CJ Day MT Drayson 2005 Effective therapeutic use of rituximab in refractory Wegener's granulomatosis Nephrol Dial Transplant 20 3 622 625
49. KA Keogh SR Ytterberg FC Fervenza 2006 Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial Am J Respir Crit Care Med 173 2 180 187
50. R Stasi E Stipa G Del Poeta 2006 Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab Rheumatology (Oxford) 45 11 1432 1436
51. KP Ng MJ Leandro JC Edwards 2006 Ann Rheum Dis 65 7 942 945
52. PM Aries B Hellmich J Voswinkel 2006 Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations Ann Rheum Dis 65 7 853 858
53. E Kimby 2005 Tolerability and safety of rituximab (MabThera) Cancer Treat Rev 31 6 456 473
54. CM Bennett ZR Rogers DD Kinnamon 2006 Blood 107 7 2639 2642
55. JS Smolen EC Keystone P Emery 2007 Consensus statement on the use of rituximab in patients with rheumatoid arthritis Ann Rheum Dis 66 2 143 150
56. JH Anolik J Barnard A Cappione 2004 Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus Arthritis Rheum 50 11 3580 3590
57. F Lavie C Miceli-Richard M Ittah 2007 Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production Ann Rheum Dis 66 5 700 703
58. T Vallerskog M Heimburger I Gunnarsson 2006 Differential effects on BAFF and APRIL levels in rituximab treated patients with systemic lupus erythematosus and rheumatoid arthritis Arthritis Res Ther 8 6 R167